Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

DSpace/Manakin Repository

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome

Citable link to this page

 

 
Title: Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome
Author: Khwaja, O. S.; Ho, E.; Barnes, K. V.; O, H. M.; Pereira, Luis Marcelo; Finkelstein, Y.; Nelson, Charles A.; Vogel-Farley, V.; DeGregorio, G.; Holm, Ingrid Adele; Khatwa, Umakanth A.; Kapur, Kush; Alexander, Mark Edward; Finnegan, D. M.; Cantwell, N. G.; Walco, A. C.; Rappaport, Leonard Allan; Gregas, M.; Fichorova, Raina Nakova; Shannon, M. W.; Sur, M.; Kaufmann, Walter E

Note: Order does not necessarily reflect citation order of authors.

Citation: Khwaja, O. S., E. Ho, K. V. Barnes, H. M. O’Leary, L. M. Pereira, Y. Finkelstein, C. A. Nelson, et al. 2014. “Safety, Pharmacokinetics, and Preliminary Assessment of Efficacy of Mecasermin (recombinant Human IGF-1) for the Treatment of Rett Syndrome.” Proceedings of the National Academy of Sciences 111 (12) (March 12): 4596–4601. doi:10.1073/pnas.1311141111.
Full Text & Related Files:
Abstract: Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder mainly affecting females and is associated with mutations in MECP2, the gene encoding methyl CpG-binding protein 2. Mouse models suggest that recombinant human insulin-like growth factor 1 (IGF-1) (rhIGF1) (mecasermin) may improve many clinical features. We evaluated the safety, tolerability, and pharmacokinetic profiles of IGF-1 in 12 girls with MECP2 mutations (9 with RTT). In addition, we performed a preliminary assessment of efficacy using automated cardiorespiratory measures, EEG, a set of RTT-oriented clinical assessments, and two standardized behavioral questionnaires. This phase 1 trial included a 4-wk multiple ascending dose (MAD) (40–120 μg/kg twice daily) period and a 20-wk open-label extension (OLE) at the maximum dose. Twelve subjects completed the MAD and 10 the entire study, without evidence of hypoglycemia or serious adverse events. Mecasermin reached the CNS compartment as evidenced by the increase in cerebrospinal fluid IGF-1 levels at the end of the MAD. The drug followed nonlinear kinetics, with greater distribution in the peripheral compartment. Cardiorespiratory measures showed that apnea improved during the OLE. Some neurobehavioral parameters, specifically measures of anxiety and mood also improved during the OLE. These improvements in mood and anxiety scores were supported by reversal of right frontal alpha band asymmetry on EEG, an index of anxiety and depression. Our data indicate that IGF-1 is safe and well tolerated in girls with RTT and, as demonstrated in preclinical studies, ameliorates certain breathing and behavioral abnormalities.
Published Version: doi:10.3389/fnhum.2013.00444
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13548951
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters